Teleost invariant chain cancer vaccine
AssigneeNouscom AG
InventorsAlfredo Nicosia, Elisa Scarselli, Armin Lahm
Life of this patent
Estimating the term…
Abstract
The present invention relates to polypeptides comprising a fragment of a teleost invariant chain optionally fused to one or more antigens or a teleost invariant chain fused to one or more antigens or antigenic fragments thereof, a polynucleotide encoding such polypeptides, vectors comprising such polynucleotides, collection of vectors comprising such polynucleotides and use of such polypeptides, polynucleotides, vectors for treating or preventing diseases, in particular tumor diseases. The teleost invariant chain polypeptides or fragments thereof act as “T cell enhancer” converting non-immunogenic antigenic sequences into immunogenic T cell antigens.
Claims9
A method for treating or limiting the development of a cancer comprising administering to a subject in need thereof a polynucleotide or a vector comprising said polynucleotide, in an amount effective to limit the development of or treat said cancer, wherein the polynucleotide encodes a polypeptide consisting of a fragment of an invariant chain (INV) of a Teleostei consisting of between 16 to 27 contiguous amino acids of the membrane proximal domain (MPD) of the INV of the Teleostei, wherein the fragment has T cell response enhancer activity and the MPD is characterized by an amino acid sequence selected from SEQ ID NOs:
- 3, 4, 10, and 11;
- and one or more cancer-specific antigens or cancer-specific neoantigens and/or one or more antigenic fragments thereof.
A method for inducing an immune response in a subject comprising administering to the subject a polynucleotide or a vector comprising said polynucleotide, wherein the polynucleotide encodes a polypeptide consisting of a fragment of an invariant chain (INV) of a Teleostei consisting of between 16 to 27 contiguous amino acids of the membrane proximal domain (MPD) of the INV of the Teleostei, wherein the fragment has T cell response enhancer activity and the MPD is characterized by an amino acid sequence selected from SEQ ID NOs:
- 3, 4, 10, and 11;
- and one or more cancer-specific antigens or cancer-specific neoantigens and/or one or more antigenic fragments thereof.
Dependencies are inferred from the claim text.